CTI Launches 3rd Swiss–Korean Innovation Project Call

Following the first and second successful calls of 2015 and 2016, the Korea Institute for Advancement of Technology (KIAT) and the Commission for Technology and Innovation (CTI) are launching a third call for joint innovation projects between Switzerland and South Korea.

Who is the call aimed at?
• The call for joint innovation projects is aimed at companies and research institutions in Switzerland and South Korea (consortia) looking to carry out a joint science-based innovation project.
• It is aimed for Swiss and South Korean companies which see the two countries as a major market and research locations; and which want to take advantage of the benefit from KIAT and CTI funding.
• The Call is open for all topics, but focuses on the development of products and services within (1) biotechnology, (2) medtech and (3) information and communication technology (ICT).

What conditions apply?
This is an international, bilateral funding measure subject to the funding rules of KIAT and the CTI. Details are published in the call documentation. The call was launched 8 March 2017.

The funding organisations will be glad to advise interested parties on request.

Which criteria must be met?
• The basic requirements for setting up a consortium must be met; in particular, the skills and expertise of the Swiss and South Korean partners should be complementary.
• The planned project brings benefits to the project partners in both countries.
• The planned innovation project is clearly market-oriented.
• Please refer to CTI’s website (www.kti.admin.ch) for full conditions.

What is the call procedure?
The call is being conducted in a single stage procedure. Consideration should be given to the following points:
• Launch of the call is 08 March 2017.
• The closing date for submissions is 19 June 2017.
• The joint application together with the CTI application form for Swiss partners and the KIAT application form for partners from South Korea must be written in English. The consortia submits simultaneously to both funding agencies (joint application and CTI application to the CTI, joint application and KIAT application to KIAT).
• Notification of the evaluation results is beginning of October 2017

Contacts: Alain Dietrich: alain.dietrich@kti.admin.ch; Barbara Pfluger: barbara.pfluger@kti.admin.ch
### Korean Company Profiles and Co-operation Interests

<table>
<thead>
<tr>
<th>Company</th>
<th>Your Fields of Research</th>
<th>Your Competencies</th>
<th>Website</th>
<th>In which technology fields of Swiss partners are you interested?</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATI Biosystems</td>
<td>Lab automation</td>
<td>System design, development and manufacturer of automated systems. We have dedicated software engineers and system engineers capable of producing and operating various automated systems. Our greatest competencies is that we have the resources to develop customized lab automation that can satisfy the unmet needs in the biotechnology automation industry.</td>
<td><a href="http://www.bioautomation.co.kr">www.bioautomation.co.kr</a></td>
<td>Partners in the fields of bioprinting of organoids (organ tissue). More specifically, we want to partner with a research institution in the fields of testing drugs or treatment on organ tissues (ex. liver tissue) that requires &quot;cell printing.&quot; We also want to find a partner with experience in valve and dispensing technology to dispense cells.</td>
</tr>
<tr>
<td>HWANGSUNG Co.</td>
<td>Sensor - 3DTLSENS (3D TouchLess safety SENSOR)</td>
<td>The project comprises the design and development of a new distributed 3DTLSENS able to detect the variation of the capacity caused by a change of the surrounding conditions. The 3DTLSENS system is composed by grounded plate and a stripe, which acts as another plate, thus forming a capacitor. An electric field is generated if the stripe is polarized to a certain voltage value. The electric field can be affected by a surrounding variation like, for example, the presence of an object which causes the variation of the capacitance between the stripe and ground. If the polarized voltage is a frequency-controlled signal, the variation of the electric field can be easily detected by closing the signal generator in a loop control.</td>
<td><a href="http://eng.electricstep.kr/index.php?language=eng">http://eng.electricstep.kr/index.php?language=eng</a></td>
<td>Research Institutes within industry that need 3D Sensors(3DTLSENS).</td>
</tr>
<tr>
<td>KAIST, Department of Bio&amp;Brain Engineering</td>
<td>Microtechnology, MEMS</td>
<td>Micro Sensors for Human Physiological Stress</td>
<td><a href="http://mems.kaist.ac.kr">http://mems.kaist.ac.kr</a></td>
<td>Human Stress &amp; Emotion Monitoring</td>
</tr>
<tr>
<td>Kangwon National University, Systems Immunology</td>
<td>Therapeutic target discovery, therapeutic and diagnostic antibody and antibody conjugate development</td>
<td>Discovery &amp; development of biothugs including mAb and ADCs Applied protein chemistry</td>
<td><a href="http://si.kangwon.ac.kr/bbs/con-">http://si.kangwon.ac.kr/bbs/con-</a> tent.php?co_id=su07_2_3</td>
<td>Institute or biotech company interested in enrichment of therapeutic pipelines and targeted drug discovery</td>
</tr>
<tr>
<td>Kyungpook National University, Laser Application Center, Institute of Advanced Convergence Technology</td>
<td>Biomedical Optics, Medical devices Laser processing</td>
<td>Laser-Tissue Interaction(diagnosis/therapy); Laser [rning[metal-ceramic]</td>
<td></td>
<td>Laser applications</td>
</tr>
<tr>
<td>NGeneBio Co., Ltd.</td>
<td>Next generation sequencing (NGS) based in vitro diagnostics (IVD) product development Clinical bioinformatics Clinical NGS data analysis pipeline &amp; SW development</td>
<td>NGS assay/panel developer which is interested in fvd product development combined with fvd analysis SW Cancer genetic marker-targeting drug developer which is interested in solution for companion molecular diagnostics Commercial genetic testing labs which is interested in development of NGS-based fvd testing assay Pharmacogenomics developer which is interested in companion diagnostics</td>
<td><a href="http://ngenebio.com/">http://ngenebio.com/</a></td>
<td></td>
</tr>
<tr>
<td>OBELAB, Inc.</td>
<td>Neuroimaging</td>
<td></td>
<td><a href="http://www.obelab.com">www.obelab.com</a></td>
<td>Biotechnology, Bio signal data analysis, Big data manipulation</td>
</tr>
<tr>
<td>PCL Inc.</td>
<td>In Vitro Diagnostics</td>
<td></td>
<td><a href="http://www.pclchip.com">www.pclchip.com</a></td>
<td>Medical device for POCT</td>
</tr>
<tr>
<td>Qurient, Co., Ltd.</td>
<td>Cancer, Immuno-oncology</td>
<td>Based on biology and pharmacology, we want to strengthen our pipelines.</td>
<td><a href="http://www.qurient.com">www.qurient.com</a></td>
<td>Companies that can pursue an added-value for our program. Partnership is considering co-development for risk sharing. Qurient oncology program: TAM PTK inhibitor (preclinical), CDK7 Inhibitor (lead optimization) In licensing: Small molecule with anticancer effect in discovery stage</td>
</tr>
<tr>
<td>SEIL TECHNIO CORP.</td>
<td>IT, OPTIC R&amp;D</td>
<td>IT, OPTIC R&amp;D</td>
<td><a href="http://www.seilvision.co.kr">www.seilvision.co.kr</a></td>
<td></td>
</tr>
<tr>
<td>Seoul National University, Mechanical Engineering</td>
<td>Microfluidics, organ on a chip</td>
<td>Organ on a chip</td>
<td><a href="http://imbet.snu.ac.kr/professor.html">http://imbet.snu.ac.kr/professor.html</a></td>
<td>Biotech and medtech interested in a Organ-on-a-chip microfluidic platform.</td>
</tr>
<tr>
<td>Seoul National University, Molecular Medicine &amp; Biopharmaceutical Sciences</td>
<td>Therapeutic target discovery: in-situ identification of phenotypic cell surface markers</td>
<td>IP-MS and chemical crosslinking analytic platforms discovering ligand-receptor &amp; Ab-antigen pairs</td>
<td><a href="http://tcpl.snu.ac.kr/">http://tcpl.snu.ac.kr/</a></td>
<td>Institute or Biotech interested in enrichment of therapeutic pipelines and targeted drug discovery</td>
</tr>
<tr>
<td>UXEnterprise</td>
<td>Woman's healthcare</td>
<td>Smart wearable device for prevent women's disease</td>
<td><a href="http://www.ybrain.com">www.ybrain.com</a></td>
<td>Healthcare, biomedical , biosignal analysis, hospitals,pharmaceutical company</td>
</tr>
<tr>
<td>Ybrain Inc.</td>
<td>Medical Treatment Device based on Non-Invasive Brain Stimulation</td>
<td>Home Treatment + Mobile Services</td>
<td><a href="http://www.yonsei.ac.kr">www.yonsei.ac.kr</a></td>
<td>Stroke Rehabilitation</td>
</tr>
<tr>
<td>Yonsei University, Material Science and Engineering</td>
<td>Medical technology</td>
<td>Gas sensor</td>
<td></td>
<td>Sensor chip fabrication For the preparation of &quot;3. Korea-Switzerland Joint R&amp;D projects&quot;, we are currently conducting a technological collaboration with the partner manufacturing sensors in the Switzerland, and we are planning to take part in the &quot;3rd S. Korea-Switzerland Call for Joint R&amp;D projects&quot; to discuss</td>
</tr>
</tbody>
</table>
Program of the Korean Delegation

Participants of the Korean Delegation

- Ki Hyun KIM, HWANGSUNG Co., Ltd, Executive Director
- Hu Sang SHIN, HWANGSUNG Co., Ltd, Executive Officer
- Hanseok YUN, OBELAB, Inc., Chief Operating Officer
- Noo Li JEON, Seoul National University, Professor
- Seohyun AHN, Qurient, Co., Ltd., Director
- YoungJoon MOON, NGeneBio Co., Ltd., Director
- Soyoun KIM, PCL Inc., CEO
- Ye Chan SHIN, ATI Biosystems, Manager
- Young-Ho CHO, KAIST, Professor
- Ye Jin LEE, UXEnterprise, CEO
- Kristine M. KIM, Kangwon National University, Professor
- Eugene C Yi, Seoul National University, Professor
- Jung Seok KIM, SEIL TECHNO CORP., PRESIDENT
- Wooyoung, Lee, Yongsei university, Professor
- Yong-Sahm CHOE, iSenLab Inc., CEO
- Gu-In JUNG, Kyungpook National University, Senior Researcher
- Su-Won KIM, Kyungpoong National University, Senior Researcher
- Jiyunyun LIM, Swiss Embassy, Deputy Head(STO)
- Somi YOON, Korea Institute for Advancement of Technology, KIAT, Senior Researcher

An interesting program has been organized together with and for the CTI by members of the NTN Swiss Biotech.

Wednesday, 19 April 2017:

Morning at ETH Zürich-Hönggerberg with presentations by:
- Prof. Dr. Ernst Hafen, ETH Zürich, Health Data Ownership
- Hr. Michael Stucky, Wyss Translational Center, Presentation of the Center
- Dr. Maximilian Emmert, Wyss Translational Center, Life Matrix
- Dr. Daniel Stekhoven, ETH/Nexus, Clinical Bioinformatics
- Prof. Dr. Bernd Wollscheid, ETH Zürich, Proteomics
- Prof. Dr. Noo Li Jeon, Seoul National University, Microfluidic Platform for Organ-on-a-chip

Afternoon within the premises of Molecular Partners in Schlieren:
- Dr. Reto Näf, Topadur AG, Wound Healing
- Dr. Silke Schneider, Competence Center Personalized Medicine ETH/UZH, Introduction and Activities of the Competence Center
- Dr. Olivier Frey, Insphero AG, 3D-Tissues
- Prof. Dr. Markus Seeger, University Zürich, Antibiotics Platform of NTN Swiss Biotech
- Prof. Dr. Michael Raghunath, UAS, Wädenswil, Zürich, TEDD Platform of NTN Swiss Biotech
- Soyoum Kim, PCL Inc., Novel 3D biomarker immobilization technology
- Prof. Dr. Young-Ho Cho, KAIST, Skin Patches for Human Stress Monitoring

Thursday, 20 April 2017

Morning on the premises of F. Hoffmann-La Roche in Basel:
- Mrs. Patricia Fischer, Roche, General Information
- Dr. Franz Schuler, Laboratory visit

Afternoon at the UAS NW in Basel:
- Dr. Lope Florez, Genedata Basel, Software and Services
- Dr. Thomas Hafen, Bühlmann Laboratories, in vitro Diagnostics
- Paul R. Hofer, Hutman Diagnostics, Molecular Diagnostics
- Prof. Dr. Falko Schlottig, UAS NW-Switzerland, School of Life Sciences, Research at Universities of Applied Sciences
- Prof. Dr. Veronika Butterweck, UAS NW-Switzerland, Plant and Herb Medicine
- Dr. Young Joon Moon, NgeneBio Co. Ltd., Next Generation based Sequencing based cancer based IVD assay
- Dr. Seohyun Ahn, Qurient Co. Ltd., Introduction to Oncology Program